pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 36 | Non-oncology: 24 Oncology: 12 |
| Under Consideration for Negotiation | 17 | Non-oncology: 5 Oncology: 12 |
| Completed Negotiations | 870 | With Letter of Intent: 754 Without agreement: 116 |
| Negotiations That Were Not Pursued | 111 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Tremfya | Janssen Inc. | Crohn's disease | |
| Opdivo-Yervoy | Bristol Myers Squibb Canada Inc. | For the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. | |
| Pombiliti with Opfolda | Amicus Therapeutics Canada Inc. | Pompe disease | |
| Piasky | Hoffmann-La Roche Ltd. | Paroxysmal nocturnal hemoglobinuria (PNH) | |
| Longavo | Teva Canada Innovation | Schizophrenia in Adults | |
| Calquence | AstraZeneca Canada Inc. | In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated MCL who are ineligible for autologous stem cell transplant. | |
| Omvoh | Eli Lilly Canada Inc. | Crohn's disease | |
| Penthrox | Knight Therapeutics Inc. | Adult patients undergoing minor gynecological, ambulatory, or emergency procedures |